💥Super excited to share our review in @NatureRevCancer ! We dive into cross-priming, cDC1s, their role in tumors, and strategies to enhance their function in cancer immunotherapy 🧬🔬Grateful to @DrIgMelero & all authors! 👉🏻https://t.co/dL5wKjcK85 #cDC1#immunotherapy
📢 Tomorrow begins the RNA Symposium at Cima! International experts will discuss the latest advances in RNA-based therapies, genetic regulations and more. 🧬 Don't miss out, keep an eye on updates coming soon!
💫Hoy felicitamos a nuestro investigador @Teijeira_ITLive, galardonado en las #BecasLeonardo 2023 de @FundacionBBVA.
🎯Su proyecto se centra en desarrollar un nuevo fármaco biológico que mejore la eficacia de la #inmunoterapia contra el cáncer
https://t.co/ObDO02yoyW
Hoy hace justo un año que empezamos a redactar el proyecto Immune4all.
Hoy estamos en pleno desarrollo, cogiendo velocidad. Hemos tenido nuestra reunión mensual del comité director.
💪🏾💪🏾Como dice la primera foto: "lo mejor está por venir"
@CIBERONC @CIBERehd @CIBER_ISCIII
Dev therap: Targeting microemv Visugromab (anti-GDF15) w/ anti PD-1 interesting perspectives. #ASCO2023 by Prof I. Melero. BAY2416964 AhR inhib on heav pretreat with no responses in NSCLC( combos?)excellent discussion of @PatelOncology#ASCO23#CancerResearch#NSCLC
ICYMI: @ClinicaNavarra's Dr. Ignacio Melero @DrIgMelero, a former CRI CLIP Investigator, presented "Interleukin-8, neutrophils and NETs in a druggable collusion against cancer immunotherapy" on Sunday at #AACR23! #CancerResearch
At the #AACR2023? Please join our Major Symposium on Myeloid Cell Modulation in Cancer, this afternoon at 1 pm. With great talks by Michele de Palma, @DrIgMelero , NextGen star @mk_ruhland and me.
In the March issue of Cancer Discovery—
CD137 (4-1BB)-based cancer immunotherapy on its 25th anniversary, by @DrIgMelero et al.
https://t.co/3UkkmLFhFw
@ClinicaNavarra@CIMA_unav
🎉🏆And the winner of the II Getica's Research Awards is... Irene Olivera!Congratulations Irene & team, we are absolutely amazed and proud of the work you performed in @CIMA_unav, “A therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα and IL-1β”Well done!
Patricia Andrés, número uno del #MIR2023 🥳
¡ENHORABUENA!
➡️ El 97,13 % de los graduados de #MedUNAV presentados al examen obtiene una de las 8550 plazas ofertadas por el Ministerio de @sanidadgob y el 40% se sitúa entre los 2000 primeros puestos.
👉 https://t.co/vLAAzDQONC